Gujarat Kidney and Super Speciality made a constructive entry into the Indian equity markets on December 30, 2025, with its shares opening at a premium over the IPO issue price. The listing reflected steady investor confidence in the healthcare company following a well-subscribed public offering.
The shares listed at ₹120.75 on the BSE and ₹120 on the NSE, translating into a premium of 5.92% and 5.26%, respectively, over the IPO issue price of ₹114.
IPO Size and Subscription Overview
The ₹251 crore initial public offering was structured entirely as a fresh issue and was priced at the upper end of the band at ₹114 per share. The issue attracted healthy interest from investors across categories, resulting in an overall subscription of 5.21 times.
Retail investors led the demand, subscribing 19.04 times their allotted quota. Non-institutional investors subscribed 5.73 times, while the qualified institutional buyers portion was booked 1.06 times of the non-anchor allocation. This balanced participation supported a stable debut despite measured expectations.
Anchor Investor Participation
Ahead of the public issue, the company raised ₹100 crore from anchor investors. This institutional backing provided additional credibility to the offering and helped anchor pricing expectations during the listing process.
Valuation Context at Listing
At the issue price, Gujarat Kidney and Super Speciality was valued at approximately 42 times its post IPO earnings based on FY25 figures. The stock also commanded a valuation of over 22 times book value. While these multiples are relatively elevated, they reflect the company’s recent financial expansion and sector positioning.
Business Profile and Operations
Founded in 2019, Gujarat Kidney and Super Speciality operates a network of seven multispeciality hospitals along with four pharmacies across Gujarat. The company has an operational capacity of around 340 beds and maintains a focused presence in renal sciences and super-speciality medical procedures.
The hospital chain follows an asset-light operating model, relying largely on leased facilities while pursuing selective inorganic expansion to scale operations.
Financial Performance Snapshot
The company reported strong growth in FY25, with revenue rising more than six times compared with the previous year. Profit after tax increased more than fourfold, supported by higher occupancy levels and improving operating efficiencies. EBITDA margins crossed 41% during the year, highlighting operational leverage, although sustainability remains an area investors will continue to monitor in a competitive healthcare landscape.
Use of IPO Proceeds
Funds raised through the IPO are primarily earmarked for expansion initiatives and acquisitions. Planned utilisation includes the proposed acquisition of Parekhs Hospital in Ahmedabad, setting up a new hospital facility in Vadodara, and supporting inorganic growth opportunities. These initiatives are aimed at strengthening the company’s regional footprint and long-term growth trajectory.
Conclusion
The listing of Gujarat Kidney and Super Speciality at a near 6% premium represents a measured yet positive market debut. Supported by strong retail participation, anchor investor backing, and robust recent financial growth, the company enters the public markets with a clear expansion roadmap. Market participants will now closely track execution outcomes as the business moves into its next phase of growth as a listed entity.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
